BIIB long (pattern + earning)Comment into chart
First entry point 280 (as it is now) > if this is a "head-shoulders"
TP 1 > 297 | TP2 > 302 | TP3 > 311
(SL 276)
Second entry point 268 (if bad earnings) > 0.5 retracement + patern D point
TP 1 > 276 | TP2 > 285 | TP3 > 297
(SL 264)
Ref >
> www.barrons.com
> www.barrons.com
> www.fool.com
> swingtradebot.com
> www.chartmill.com
4BIIB trade ideas
Channel + support + doji + double bottom + 11:1 RRBIIB is in a channel and is in a buy low, sell high situation
The RR on this trade is 11:1:
Trigger: 272.98
Stop: 267.86
Target: 329.36
Plan:
Not sure if this trade will trigger because it is at a strong support and has formed a possible double bottom drawn in blue. I will leave this trade open for the rest of the week. If triggered I will set and forget stop and target triggers
The lowest low of the channel is 268 and my stop is below that for a conservative play.
BIIB is setting up and there are a few ways to play itBIIB is setting up in what can be viewed as either a 3 weeks tight pattern AND/OR a pennant on both the daily and weekly charts. This pattern is coming right after breaking out of a 4 month long double bottom and is forming on very low volume.
This pattern is constructive particularly after this breakout because this breakout came straight off the bottom starting on 11/4. Between 11/4 and 11/9, BIIB rallied over 20%. The fact that it is digesting those gains on very low volume and low price volatility is a sign that shareholders are not eager to take profits just yet.
At this point I am looking for a breakout above 325.30 to trigger a long entry. If triggered, my stop will be below support at 313.31
Buy Biogen on Fundamentals. Target $375 for 2017I´ll make it simple.
1) Really promising reseachs on Alzheimer drug.
2) Atm there are 9.9MILLION new diagnoses of demencia every year(increasing market) this number is 30% more than what the worlds health organization predicted in 2010... hense the undervalue.
3) Increasing Profits
4) EPS at 4,71 higher than what many predicted.
5) Good administration.
Forgot why I thought this is a Long"Biogen Inc. said its investigational therapy for the early stage of Alzheimer’s disease was granted fast-track designation by the U.S. Food and Drug Administration, a designation intended to bring promising drugs for serious conditions to market faster." www.marketwatch.com this news with a positive earnings may see that the stock continues to move higher this quarter. If the near term resistance line is not overcome a short position may be entered, but the reversal in the CMF on positive news may prove to support a higher move.
BIIB - Watch (Investment & potential swing trade)1D:
1W:
BIIB has gotten hammered and I feel it's over done. Since last gap down, it has been in a down trend with LHs & LLs. I'm hesitant to jump in until I see more technical justification. It is close to a support. I would like a retest and bullish candles before entering for a swing trade.